| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0003 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0004 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.2 | 0.0004 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.2 | 0.0004 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.23 | 0.0005 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.21 | 0.0007 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0008 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0008 |
| mRNA | necrostatin-7 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0009 |